Summit Therapeutics' Lung Cancer Drugs Show Mixed Results but Promising Survival Trends
Summit Therapeutics' lung cancer drug ivonescimab shows promising results in China but weaker and non-significant benefits in North America and Europe, potentially complicating its approval process in Western markets due to geographic disparities in trial outcomes.